

Overview of Disability Data Disseminated by CDCs Division of Human Development and Disability

2014 Annual Disability Statistics Compendium:
CDC Disability Statistics: Recent and Future Developments

Brian S. Armour, PhD

December 3, 2014

DHDD Teams

- ❑ Disability Research and Epidemiology Team
 - Disability and Health Data System – Dianna Carroll, Michelle Sloan

- ❑ Early Hearing Detection and Intervention (EHDI)
 - EHDI-Infant Screening – Marcus Gaffney

- ❑ Rare Disorders and Health Outcomes Team
 - Spina Bifida Patient Registry – Judy Thibadeau, Julie Bolen
 - Fragile X Syndrome Registry – Catharine Riley
 - Muscular Dystrophy Surveillance Tracking and Research Network – Natalie Street

- ❑ Child Development Studies Team
 - Diagnosis and Treatment of ADHD – Joseph Holbrook

Disability and Health Data System (DHDS)

- ❑ Source for state-based data on the health of PWDs

- ❑ Developed using CDCs Behavioral Risk Factor Surveillance System

- ❑ DHDS
 - State level disability surveillance tool
 - Open and accessible online (<http://dhds.cdc.gov/>)
 - Provides reliable, standard, and timely information
 - Approximately 80 health and demographic indicators
 - Stratified by Disability (2004 to 2012)
 - Disability Associated Health Care Expenditures
 - Public Payer (Medicare and Medicaid), Private Payer, Total

DHDS Recent Data Updates

- ❑ 2012 BRFSS estimates recently added
- ❑ Disability data by demographic groups now available for all indicators
- ❑ P-values are now available for all disparity estimates
- ❑ Dual Area Profiles
 - Ability to compare two geographic areas side-by-side on number of health indicators

DHDS New Features

- ❑ Interactive Map for Mobile Devices
 - Standard and High Contrast
 - Can be viewed on any smartphone, tablet, and all web browsers except Internet Explorer 8 or earlier

- ❑ DHDS Tutorial Videos
 - Four videos available on DHDS Homepage or YouTube
 - Introduction to DHDS
 - Interactive Map
 - Customizable Data Table
 - State Profiles

Early Hearing Detection and Intervention (EHDI)

- ❑ CDC EHDI supports the development of state-based EHDI Information Systems (EHDI-IS) to ensure deaf and hard of hearing infants receive recommended diagnostic and intervention services
- ❑ Early identification of hearing loss and intervention can help ensure children are able to reach their full potential
- ❑ Data obtained from an annual survey of programs in 50 states, 6 territories and the District Of Columbia
 - CDC EHDI Hearing Screening and Follow-up Survey
 - www.cdc.gov/ncbddd/hearingloss/ehdi-data.html

EHDI DATA 2012

State and Territorial EHDI Program Data	N	(%)
Total Births	3,953,986	
Screened (<i>excluding deaths and refusals</i>)	3,820,624	(97.1)
Failed Screening	52,961	
Documented Diagnosed (<i>based on failed screening</i>)		
Hearing Loss	5,475	
No Hearing Loss	23,603	
Diagnosed	29,078	(54.9)
No documented diagnosis*	23,883	(45.1)
*In process, died, moved, loss to follow-up.		

EHDI Current Work and Future Directions

- ❑ Making progress identifying deaf and hard of hearing infants and providing early intervention services
 - However despite continued progress, some U.S. infants are still not documented as receiving recommended testing and intervention

- ❑ CDC MMWR Supplement (September 12, 2014 / Vol. 63)

- ❑ Future Work
 - Supporting states in the continued development and enhancement of their EHDI-IS
 - Lead efforts to improve interoperability between child health data systems and advance the exchange of data between providers and public health programs
 - Develop improved ways to collect and analyze data to better assess progress and highlight areas for improvement

Spina Bifida (SB) Program

- ❑ Spina bifida is the most common permanently disabling congenital condition in the U.S.
 - More than 70,000 Americans are living with SB
 - SB occurs in 3.4 per 10,000 live births in the US

- ❑ Limitations to current SB research include few:
 - Multisite studies; randomized control trials; studies on long-term treatment outcomes

- ❑ Variation across SB clinical programs in terms of structure; services; staffing; and, care delivered

Spina Bifida Association (SBA) Patient Registry

- SBA and CDC established Spina Bifida Patient Registry to:
 - Identify best practices for SB care
 - Implement use of a shared electronic reporting system to set standards for completeness, timeliness, and quality of data among SB clinics
 - Collect longitudinal data to evaluate current medical interventions
 - Help support clinical research and a systematic approach to improving quality of care
 - Compare SB patient care among clinics, population groups, and geographic areas
 - Guide and help prioritize future SB research areas

Funded Sites, Publications and Future Work

□ Data collection

- began 2009, 10 clinics
- 14 clinics funded 2014-2019
- longitudinal data on over 4000 patients

□ Papers

- Methods Paper, Thibadeau, et al, 2012
- Descriptive paper, Sawin, et al, 2014
- Future work
 - Pressure Ulcer data analysis paper
 - Demographics paper

Fragile X Online Registry With Accessible Research Database


- ❑ Fragile X Syndrome (FXS) is the most common known inherited cause of intellectual disability
 - Estimated prevalence: 1 in 4,000 - 5,000 males and 1 in 6,000 – 8,000 females
 - People who have FXS show a range of intellectual disability and may also experience emotional, behavioral, sensory, and/or social difficulties
- ❑ Information is needed to
 - Enhance the understanding of FXS, its co-occurring conditions and its risk factors
 - Identify service barriers and needs
 - Determine the effect of current services on health
 - Document medical and behavioral treatment use and efficacy

FORWARD Registry and Longitudinal Database

- ❑ CDC supports the Fragile X Clinical and Research Consortium (FXCRC) to implement FORWARD
- ❑ Data Sources:
 - REGISTRY: a one-time Registration Form - individuals with pre and full mutation FXS and their family members (both affected and unaffected).
 - LONGITUDINAL DATABASE: Clinician Report Form, Parent Report Form, and standardized parent-report instruments on behavior and communication (i.e. SRS, SCQ, ABC) - focused on full mutation FXS patients aged 0-24 years.
- ❑ Data Collection
 - Pilot study (2008-2011): data on 276 individuals with full mutation FXS collected from 9 clinics
 - FORWARD Registry and Database (2011 – current):
 - Registry includes data on over 2,000 individuals
 - Longitudinal database includes data over 500 individuals with full mutation FXS
 - 25 clinics participating (24 clinics as of June 2014)

Fragile X Consortium

- ❑ FXCRC has established a process for clinicians/researchers to request analyses of de-identified data or access to registrants through the clinics.... see www.fxcr.org
- ❑ All requests are reviewed by the Application Review Committee





The Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet)

□ Background

- Muscular Dystrophies (MD) are a group of rare inherited disorders characterized by progressive muscle weakness and wasting
- Vary by age of onset, muscle groups affected, genes involved, severity, and progression of disease
- Population-based studies needed to more accurately estimate prevalence and mortality, and describe access to care and treatments

□ MD STARnet Objectives

- Characterize prevalence, natural history, healthcare service use and costs, and disparities in access to care
- Assess whether specific treatments, interventions, or changes in healthcare use are associated with disease progression and survival

MD STARnet Data Sources

- ❑ Medical records
 - Clinics, hospitals, etc.
 - Search using criteria (ICD code, birth year, resident)
 - Trained abstractors input data
 - Require reporting law or IRB review (approval or exemption)

- ❑ Administrative data
 - Birth and death records (state and NDI)
 - Hospital discharge
 - Medicaid (Colorado)

- ❑ Interview and surveys

MD STARnet Data

□ Data Collection

- Began for Duchenne/Becker in 2002. For all MDs in 2011.
- Currently 6 funded sites: Colorado, Iowa, 12 counties in Western New York, South Carolina, Utah/Nevada, North Carolina (piedmont area)
- Longitudinal data collection

□ With this data we plan to

- Identify geographical distribution of individuals with each type of MD and their access to care and resources
- Highlight similarities and differences in treatment, morbidity, and mortality and the factors that lead to differences
- Provide information to service providers, advocates, and policy makers to improve decision making

Key MD Articles

- ❑ Centers for Disease Control and Prevention (CDC). Prevalence of Duchenne/Becker muscular dystrophy among males aged 5-24 years - four states, 2007. *MMWR Morb Mortal Wkly Rep.* 2009 Oct 16;58(40):1119-22.
- ❑ Ciafaloni E, Fox DJ, Pandya S et al. Delayed diagnosis in Duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). *J Pediatr.* 2009 Sep;155(3):380-5.
- ❑ C. Holtzer, F.J. Meaney, J. Andrews, et al. Disparities in the Diagnosis of Duchenne and Becker Muscular Dystrophy. *Genet Med.* 2011 Nov;13(11):942-7.
- ❑ R. Arias, J. Andres, S. Pandya et al. Palliative care services in families of males with Duchenne muscular dystrophy. *Muscle Nerve.* 2011 Jul;44(1):93-101.
- ❑ NA West, Yang ML, Weitzenkamp DA et al. Pattern of Growth in Ambulatory Males with Duchenne Muscular Dystrophy. *J Pediatr.* 2013 Dec;163(6):1759-1763.e1. doi: 10.1016/j.jpeds.2013.08.004. Epub 2013 Oct 6.
- ❑ D Fox, Kumar A, West NA et al. Trends with Corticosteroid Use in Males Born 1982-2001 with Duchenne Muscular Dystrophy. In press with *J Child Neurol.*
- ❑ BJ Barber, JG Andrews, Z Lu et al. Oral Corticosteroids and Onset of Cardiomyopathy in Duchenne Muscular Dystrophy. *J Pediatr.* 2013 Oct;163(4):1080-4.e1. doi: 10.1016/j.jpeds.2013.05.060. Epub 2013 Jul 15.

Attention-Deficit/Hyperactivity Disorder and Tourette Syndrome

- ❑ Attention-deficit/hyperactivity disorder (ADHD)
 - Difficulty staying focused and paying attention, difficulty controlling behavior, and over-activity
 - Childhood onset, but often lasts into adolescence and adulthood
 - 6.4 million children aged 4-17 years (11%) have an ADHD diagnosis

- ❑ Tourette syndrome (TS)
 - Motor and phonic tics that persist for >1 year
 - Tic severity typically peaks between ages 10-12 years
 - 95,000 children aged 6-17 years (0.19%) have TS

ADHD and TS Data Sources

- ❑ National Surveys
 - National Survey of Children's Health (2003, 2007, 2011-12)
 - Provides information on the prevalence of diagnosed ADHD, medication treatment, and diagnosed TS
 - National Survey of Children with Special Health Care Needs (2001, 2005, 2009)
 - Provides information on ADHD treatment including medication, behavioral therapy, and dietary supplements

- ❑ Community-based/clinical data projects
 - Tourette Syndrome Impact (2009-11)
 - Focus on tic severity, treatment costs, access to care, relationships
 - Project to Learn about ADHD in Youth (2002-2012)
 - Provides information on ADHD community prevalence, co-occurring conditions, health risk behaviors
 - Project to Learn about Youth Mental Health (2013-current)
 - Builds upon PLAY to include more focus on internalizing disorders, externalizing disorders, and TS

Highlight: National Survey – Diagnosis and Treatment of ADHD (NS-DATA)

- ❑ Contacted all parents who reported a diagnosis of ADHD or TS in National Survey of Children’s Health in 2011-12 to investigate:
 - Diagnostic context for ADHD and/or Tourette Syndrome
 - Presence of co-occurring conditions
 - Treatment types, adherence, barriers, satisfaction
 - Academic Health and Discipline
 - Family impact of ADHD and/or Tourette Syndrome

- ❑ Papers
 - Visser SN, Danielson ML, Bitsko RH, Holbrook JR, Kogan MD, Ghandour RM, et al. Trends in the Parent-Report of Health Care Provider-Diagnosed and Medicated Attention-Deficit/Hyperactivity Disorder: United States, 2003–2011. *J Am Acad Child Adolesc Psychiatry*. 2014;53(1):34-46.e32.
 - Bitsko RH, Holbrook JR, Visser SN, Mink JW, Zinner SH, Ghandour RM, et al. A National Profile of Tourette Syndrome, 2011-2012. *J Dev Behav Pediatr*. 2014;35:317-322.

Contact Information

Brian Armour
Centers for Disease Control and Prevention
1600 Clifton Road NE,
Mail Stop E-88
Atlanta, GA 30333
Tel. 404 – 498-3014
Email. barmour@cdc.gov

For more information please contact Centers for Disease Control and Prevention

1600 Clifton Road NE, Atlanta, GA 30333
Telephone: 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348
E-mail: cdcinfo@cdc.gov Web: <http://www.cdc.gov>

Disclaimer: The findings and conclusions in this presentation are those of the author and do not necessarily represent the official position of the Centers for Disease Control and Prevention.